Drug intelligence / Profile preview

EP-007

Development stage: Unknown
Lead developer: Eppin Pharma
Modality: Small Molecules

Overview

**EP-007** is a preclinical small molecule developed by Eppin Pharma, Inc., as a peptide hydrolase inhibitor. It targets enzymes involved in peptide hydrolysis, potentially for applications in reproductive health or related indications, though specific therapeutic details remain limited in public disclosures. No mechanism of action, primary indications, or clinical data are detailed beyond its preclinical status.

Beyond the preview

Go deeper on EP-007.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EP-007.

Explore the full profile